How much does the FibroGen, Inc. Securities Litigation Settlement pay?

The total settlement fund is $28.5M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.

Is the FibroGen, Inc. Securities Litigation Settlement notice real, or a scam?

JND Legal Administration is the settlement administrator for this case. Claims are filed at fibrogensecuritieslitigation.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.

When will payments from the FibroGen, Inc. Securities Litigation Settlement be sent?

Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. Payments cannot be issued until the court grants final approval and any appeals are resolved.

Claims closedsecurities

FibroGen, Inc. Securities Litigation Settlement

Last verified July 16, 2026Source: jndHow ClaimWatch verifies cases

This settlement is closed to new claims. You can still see what it was about and follow the case in court below. Looking for money you can still claim? Browse open settlements →

What happened

FibroGen and its executives allegedly misrepresented the safety profile and Phase III trial results of its anti-anemia drug Roxadustat in filings with the FDA. Investors claim the company's stock price was artificially inflated by these false statements and declined when the truth was revealed. The defendants deny all allegations of wrongdoing.

Do you qualify?

Anyone who purchased or acquired FibroGen, Inc. securities, including options, between December 20, 2018 and July 15, 2021, inclusive. Excluded are defendants, company officers and directors during the class period, their immediate family members, and entities they owned or controlled.

How to file

Contact the Claims Administrator at (877) 595-0137 or Info@FibroGenSecuritiesLitigation.com. The settlement is in distribution phase as of February 12, 2025, with ongoing rolling distributions to approved claimants. No new claims appear to be accepted as the distribution has already commenced.

Common questions

How much does the FibroGen, Inc. Securities Litigation Settlement pay?: The total settlement fund is $28.5M. Actual amounts depend on how many valid claims are filed — most settlements divide a fixed fund pro rata, so a higher claim rate means a smaller individual check. An "up to" figure is a cap, not a guarantee.
Is the FibroGen, Inc. Securities Litigation Settlement notice real, or a scam?: JND Legal Administration is the settlement administrator for this case. Claims are filed at fibrogensecuritieslitigation.com. Filing a class action claim is always free — no legitimate settlement charges you to claim, and no administrator will ask for payment, a gift card, or your full Social Security number by email or text. If a notice asks for any of those, it is not from the administrator. When in doubt, ignore the link you were sent and go to the official settlement website directly.
When will payments from the FibroGen, Inc. Securities Litigation Settlement be sent?: Class action payouts typically take 12 to 24 months after the claim deadline, and longer if the settlement is appealed. Payments cannot be issued until the court grants final approval and any appeals are resolved.

Who's involved

Plaintiffs

Cesare Grazioli
Peifa Xu

Defendants

Pat Cotroneo
Mark Eisner
K. Peony Yu
James Schoeneck
Enrique Conterno
FibroGen, Inc.

Counsel for plaintiffs

Counsel for defendants

Parties and counsel from the public court docket. Listing an attorney here isn't an endorsement, and ClaimWatch isn't affiliated with any of them.

In the news

SEC charges former FibroGen CMO for false claims on clinical trial resultsThefly.com · September 10, 2025

Headlines via NewsAPI. ClaimWatch isn't affiliated with these publications.

New to class actions?

This summary was generated from public settlement documents and may contain errors. Confirm eligibility, deadlines, and payment terms on the official settlement website before filing. ClaimWatch is not a law firm and this is not legal advice. Filing a claim is free.

Settlement fund: $28.5M
Class period: December 20, 2018 – July 15, 2021
Case: In Re FibroGen, Inc. Securities Litigation
Case number: 3:21-cv-02623-EMC
Court: U.S. District Court
Administrator: JND Legal Administration

Official settlement website →

Case status & court docket

Federal court in CaliforniaMore from California

U.S. District Court

Case terminated December 9, 2025

December 9, 2025
Final approval
MODIFIED FINAL JUDGMENT AND ORDER DISMISSING CASE. Signed by Judge Edward M. Chen on 12/8/2025. (vla, COURT STAFF) (Filed on 12/9/2025) (Entered: 12/09/2025)
December 3, 2025
Final approval
Proposed Order of Dismissal and Final Judgment by City of Philadelphia Board of Pensions and Retirement, Employees' Retirement System of the City of Baltimore, Plymouth County Retirement Association. (Kaplan, David) (Filed on 12/3/2025) (Entered: 12/03/2025)
June 13, 2025
Distribution to class
STATUS REPORT (Post Distribution Accounting) by Employees' Retirement System of the City of Baltimore, City of Philadelphia Board of Pensions and Retirement, Plymouth County Retirement Association. (Attachments: # 1 Declaration of Luiggy Segura)(Kaplan, David) (Filed on 6/13/2025) (Entered: 06/13/20
January 15, 2025
Distribution to class
Order by Judge Edward M Chen GRANTING AS MODIFIED 261 Motion for Disbursement of Funds.(vla, COURT STAFF) (Filed on 1/15/2025) (Entered: 01/15/2025)
January 7, 2025
Preliminary approval
ORDER. The Court temporarily VACATES the hearing on 261 Lead Plaintiffs' Motion for Class Distribution Order. Within a week of the date of this order, Lead Plaintiffs shall file a supplemental brief (along with any supporting evidence) explaining why the notice and administration costs are approxima
January 3, 2025
Distribution to class
CLERK'S NOTICE RESCHEDULING MOTION HEARING. Motion Hearing as to 261 MOTION for Disbursement of Funds . reset from 1/30/2025 to 2/13/2025, at 1:30 PM in San Francisco, Courtroom 05, 17th Floor before Judge Edward M Chen. ALL COUNSEL IS REQUIRED TO ARRIVE IN COURTROOM 5, 17TH FLOOR NO LATER THAN 1:00

View the full court docket on CourtListener →

More securities settlements

View all →

September 24, 2026securities

Biogen Securities Litigation Settlement

Biogen Inc. investors allege securities violations related to the company's stock during a specific period. Biogen has settled this class action litigation for $18.9 million without admitting wrongdoing.

October 6, 2026securities

NJ Bureau of Securities Settlement with Credit Suisse

Credit Suisse allegedly violated New Jersey Securities Law by making materially false and misleading statements regarding RMBS trust certificates and engaging in fraudulent practices. On October 24, 2022, the court entered a consent order requiring Credit Suisse to pay $300 million in restitution to investors. Credit Suisse neither admitted nor denied the allegations.

October 7, 2026securities

Stitch Fix Securities Litigation Settlement

Stitch Fix, Inc. is defending against a securities class action lawsuit alleging claims related to the company's stock. The company and Lead Plaintiffs have reached a proposed settlement to resolve all claims in the action.

October 9, 2026securities

Vintage Wine Securities Settlement

Vintage Wine Estates, Inc. is settling a securities class action lawsuit alleging violations of federal securities laws. The defendants do not admit wrongdoing or that any damages were suffered. The settlement resolves claims brought by shareholders who purchased Vintage Wine common stock during the class period.

$0.50–$1.08